ACE2 and chronic kidney disease: Anguiano et al. (2016) have found that baseline circulating ACE2 activity was enhanced in chronic kidney disease patients with atherosclerotic plaques when compared to patients with no plaque, suggesting that higher circulating ACE2 activity is associated with higher risk for silent atherosclerosis.